CD274 and non-small cell lung carcinoma: Similarly, pembrolizumab significantly improved OS in non-small cell lung cancer (NSCLC) patients with PD-L1 expression ≥ 50% (Hazard Ratio (HR): 0.63, p < 0.0001) [18].